nodes	percent_of_prediction	percent_of_DWPC	metapath
Eprosartan—ABCC2—Carboplatin—bone cancer	0.244	0.306	CbGbCtD
Eprosartan—ABCC2—Cisplatin—bone cancer	0.209	0.261	CbGbCtD
Eprosartan—ABCC2—Doxorubicin—bone cancer	0.14	0.175	CbGbCtD
Eprosartan—ABCC2—Methotrexate—bone cancer	0.135	0.17	CbGbCtD
Eprosartan—CYP2C9—Cisplatin—bone cancer	0.0701	0.0878	CbGbCtD
Eprosartan—ABCC2—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00199	0.098	CbGpPWpGaD
Eprosartan—ABCC2—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00186	0.0918	CbGpPWpGaD
Eprosartan—ABCC2—Irinotecan Pathway—CYP3A4—bone cancer	0.00127	0.0627	CbGpPWpGaD
Eprosartan—ABCC2—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.00109	0.0536	CbGpPWpGaD
Eprosartan—AGTR1—Arf6 signaling events—GNA11—bone cancer	0.00108	0.0532	CbGpPWpGaD
Eprosartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00107	0.0527	CbGpPWpGaD
Eprosartan—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00087	0.0429	CbGpPWpGaD
Eprosartan—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000832	0.041	CbGpPWpGaD
Eprosartan—ABCC2—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000656	0.0323	CbGpPWpGaD
Eprosartan—Eczema—Epirubicin—bone cancer	0.000651	0.0036	CcSEcCtD
Eprosartan—Abnormal vision—Doxorubicin—bone cancer	0.000651	0.00359	CcSEcCtD
Eprosartan—Losartan—CYP3A4—bone cancer	0.000646	1	CrCbGaD
Eprosartan—Tremor—Cisplatin—bone cancer	0.000643	0.00355	CcSEcCtD
Eprosartan—Ill-defined disorder—Cisplatin—bone cancer	0.000637	0.00352	CcSEcCtD
Eprosartan—Hot flush—Epirubicin—bone cancer	0.000626	0.00346	CcSEcCtD
Eprosartan—Osteoarthritis—Methotrexate—bone cancer	0.000625	0.00345	CcSEcCtD
Eprosartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000625	0.0308	CbGpPWpGaD
Eprosartan—Diabetes mellitus—Doxorubicin—bone cancer	0.000623	0.00344	CcSEcCtD
Eprosartan—Menopausal symptoms—Epirubicin—bone cancer	0.00062	0.00343	CcSEcCtD
Eprosartan—Malaise—Cisplatin—bone cancer	0.000619	0.00342	CcSEcCtD
Eprosartan—Purpura—Epirubicin—bone cancer	0.000607	0.00335	CcSEcCtD
Eprosartan—AGTR1—Arf6 signaling events—MET—bone cancer	0.000607	0.0299	CbGpPWpGaD
Eprosartan—Vascular purpura—Doxorubicin—bone cancer	0.000605	0.00334	CcSEcCtD
Eprosartan—Eczema—Doxorubicin—bone cancer	0.000603	0.00333	CcSEcCtD
Eprosartan—Cardiac failure—Epirubicin—bone cancer	0.0006	0.00331	CcSEcCtD
Eprosartan—Ataxia—Methotrexate—bone cancer	0.000588	0.00325	CcSEcCtD
Eprosartan—Hyponatraemia—Epirubicin—bone cancer	0.000588	0.00325	CcSEcCtD
Eprosartan—Osteoarthritis—Epirubicin—bone cancer	0.000585	0.00323	CcSEcCtD
Eprosartan—Myalgia—Cisplatin—bone cancer	0.000584	0.00323	CcSEcCtD
Eprosartan—Anxiety—Cisplatin—bone cancer	0.000582	0.00322	CcSEcCtD
Eprosartan—Hot flush—Doxorubicin—bone cancer	0.000579	0.0032	CcSEcCtD
Eprosartan—Discomfort—Cisplatin—bone cancer	0.000577	0.00319	CcSEcCtD
Eprosartan—Migraine—Epirubicin—bone cancer	0.000576	0.00318	CcSEcCtD
Eprosartan—Menopausal symptoms—Doxorubicin—bone cancer	0.000574	0.00317	CcSEcCtD
Eprosartan—Face oedema—Epirubicin—bone cancer	0.000565	0.00312	CcSEcCtD
Eprosartan—Purpura—Doxorubicin—bone cancer	0.000562	0.0031	CcSEcCtD
Eprosartan—Cardiac failure—Doxorubicin—bone cancer	0.000555	0.00307	CcSEcCtD
Eprosartan—Ataxia—Epirubicin—bone cancer	0.00055	0.00304	CcSEcCtD
Eprosartan—Thrombocytopenia—Cisplatin—bone cancer	0.000548	0.00303	CcSEcCtD
Eprosartan—Blood creatinine increased—Epirubicin—bone cancer	0.000548	0.00303	CcSEcCtD
Eprosartan—Tachycardia—Cisplatin—bone cancer	0.000547	0.00302	CcSEcCtD
Eprosartan—Hyponatraemia—Doxorubicin—bone cancer	0.000544	0.003	CcSEcCtD
Eprosartan—Osteoarthritis—Doxorubicin—bone cancer	0.000542	0.00299	CcSEcCtD
Eprosartan—Hyperhidrosis—Cisplatin—bone cancer	0.000542	0.00299	CcSEcCtD
Eprosartan—Asthma—Methotrexate—bone cancer	0.000541	0.00299	CcSEcCtD
Eprosartan—Orthostatic hypotension—Epirubicin—bone cancer	0.000535	0.00295	CcSEcCtD
Eprosartan—Anorexia—Cisplatin—bone cancer	0.000534	0.00295	CcSEcCtD
Eprosartan—Migraine—Doxorubicin—bone cancer	0.000533	0.00294	CcSEcCtD
Eprosartan—Hypokalaemia—Epirubicin—bone cancer	0.000533	0.00294	CcSEcCtD
Eprosartan—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000527	0.00291	CcSEcCtD
Eprosartan—Hypotension—Cisplatin—bone cancer	0.000523	0.00289	CcSEcCtD
Eprosartan—Face oedema—Doxorubicin—bone cancer	0.000523	0.00289	CcSEcCtD
Eprosartan—Gastritis—Epirubicin—bone cancer	0.000518	0.00286	CcSEcCtD
Eprosartan—Muscular weakness—Epirubicin—bone cancer	0.000516	0.00285	CcSEcCtD
Eprosartan—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000516	0.00285	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00051	0.00282	CcSEcCtD
Eprosartan—Ataxia—Doxorubicin—bone cancer	0.000509	0.00281	CcSEcCtD
Eprosartan—Blood creatinine increased—Doxorubicin—bone cancer	0.000507	0.0028	CcSEcCtD
Eprosartan—Asthma—Epirubicin—bone cancer	0.000506	0.00279	CcSEcCtD
Eprosartan—Paraesthesia—Cisplatin—bone cancer	0.000503	0.00278	CcSEcCtD
Eprosartan—Upper respiratory tract infection—Methotrexate—bone cancer	0.000502	0.00278	CcSEcCtD
Eprosartan—Dyspnoea—Cisplatin—bone cancer	0.000499	0.00276	CcSEcCtD
Eprosartan—Orthostatic hypotension—Doxorubicin—bone cancer	0.000495	0.00273	CcSEcCtD
Eprosartan—Hypokalaemia—Doxorubicin—bone cancer	0.000493	0.00272	CcSEcCtD
Eprosartan—Angina pectoris—Epirubicin—bone cancer	0.000493	0.00272	CcSEcCtD
Eprosartan—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000488	0.00269	CcSEcCtD
Eprosartan—Decreased appetite—Cisplatin—bone cancer	0.000487	0.00269	CcSEcCtD
Eprosartan—Bronchitis—Epirubicin—bone cancer	0.000486	0.00269	CcSEcCtD
Eprosartan—Depression—Methotrexate—bone cancer	0.000481	0.00265	CcSEcCtD
Eprosartan—Gastritis—Doxorubicin—bone cancer	0.000479	0.00265	CcSEcCtD
Eprosartan—Pain—Cisplatin—bone cancer	0.000479	0.00265	CcSEcCtD
Eprosartan—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000478	0.00264	CcSEcCtD
Eprosartan—Muscular weakness—Doxorubicin—bone cancer	0.000478	0.00264	CcSEcCtD
Eprosartan—Renal failure—Methotrexate—bone cancer	0.000474	0.00262	CcSEcCtD
Eprosartan—Upper respiratory tract infection—Epirubicin—bone cancer	0.00047	0.0026	CcSEcCtD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00047	0.0232	CbGpPWpGaD
Eprosartan—Conjunctivitis—Methotrexate—bone cancer	0.000468	0.00259	CcSEcCtD
Eprosartan—Asthma—Doxorubicin—bone cancer	0.000468	0.00259	CcSEcCtD
Eprosartan—Pollakiuria—Epirubicin—bone cancer	0.000467	0.00258	CcSEcCtD
Eprosartan—Feeling abnormal—Cisplatin—bone cancer	0.000462	0.00255	CcSEcCtD
Eprosartan—Haematuria—Methotrexate—bone cancer	0.00046	0.00254	CcSEcCtD
Eprosartan—Hyperglycaemia—Epirubicin—bone cancer	0.000456	0.00252	CcSEcCtD
Eprosartan—Angina pectoris—Doxorubicin—bone cancer	0.000456	0.00252	CcSEcCtD
Eprosartan—Epistaxis—Methotrexate—bone cancer	0.000455	0.00251	CcSEcCtD
Eprosartan—Bronchitis—Doxorubicin—bone cancer	0.00045	0.00249	CcSEcCtD
Eprosartan—Renal failure—Epirubicin—bone cancer	0.000443	0.00245	CcSEcCtD
Eprosartan—Body temperature increased—Cisplatin—bone cancer	0.000443	0.00245	CcSEcCtD
Eprosartan—Neuropathy peripheral—Epirubicin—bone cancer	0.000442	0.00244	CcSEcCtD
Eprosartan—Conjunctivitis—Epirubicin—bone cancer	0.000438	0.00242	CcSEcCtD
Eprosartan—Urinary tract infection—Epirubicin—bone cancer	0.000438	0.00242	CcSEcCtD
Eprosartan—AGTR1—G alpha (q) signalling events—GRM1—bone cancer	0.000438	0.0216	CbGpPWpGaD
Eprosartan—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000435	0.0024	CcSEcCtD
Eprosartan—Pollakiuria—Doxorubicin—bone cancer	0.000432	0.00239	CcSEcCtD
Eprosartan—Haematuria—Epirubicin—bone cancer	0.00043	0.00238	CcSEcCtD
Eprosartan—Pharyngitis—Methotrexate—bone cancer	0.000429	0.00237	CcSEcCtD
Eprosartan—Epistaxis—Epirubicin—bone cancer	0.000425	0.00235	CcSEcCtD
Eprosartan—Sinusitis—Epirubicin—bone cancer	0.000423	0.00234	CcSEcCtD
Eprosartan—Hyperglycaemia—Doxorubicin—bone cancer	0.000422	0.00233	CcSEcCtD
Eprosartan—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.00042	0.0207	CbGpPWpGaD
Eprosartan—Visual impairment—Methotrexate—bone cancer	0.000417	0.0023	CcSEcCtD
Eprosartan—Hypersensitivity—Cisplatin—bone cancer	0.000413	0.00228	CcSEcCtD
Eprosartan—Bradycardia—Epirubicin—bone cancer	0.000412	0.00228	CcSEcCtD
Eprosartan—Renal failure—Doxorubicin—bone cancer	0.00041	0.00227	CcSEcCtD
Eprosartan—Neuropathy peripheral—Doxorubicin—bone cancer	0.000409	0.00226	CcSEcCtD
Eprosartan—Rhinitis—Epirubicin—bone cancer	0.000406	0.00224	CcSEcCtD
Eprosartan—Urinary tract infection—Doxorubicin—bone cancer	0.000406	0.00224	CcSEcCtD
Eprosartan—Conjunctivitis—Doxorubicin—bone cancer	0.000406	0.00224	CcSEcCtD
Eprosartan—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000404	0.0199	CbGpPWpGaD
Eprosartan—Tinnitus—Methotrexate—bone cancer	0.000403	0.00223	CcSEcCtD
Eprosartan—Asthenia—Cisplatin—bone cancer	0.000402	0.00222	CcSEcCtD
Eprosartan—Pharyngitis—Epirubicin—bone cancer	0.000402	0.00222	CcSEcCtD
Eprosartan—Oedema peripheral—Epirubicin—bone cancer	0.000399	0.0022	CcSEcCtD
Eprosartan—Haematuria—Doxorubicin—bone cancer	0.000398	0.0022	CcSEcCtD
Eprosartan—Epistaxis—Doxorubicin—bone cancer	0.000394	0.00217	CcSEcCtD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.000392	0.0193	CbGpPWpGaD
Eprosartan—Sinusitis—Doxorubicin—bone cancer	0.000392	0.00216	CcSEcCtD
Eprosartan—Visual impairment—Epirubicin—bone cancer	0.00039	0.00216	CcSEcCtD
Eprosartan—Chills—Methotrexate—bone cancer	0.000388	0.00214	CcSEcCtD
Eprosartan—Diarrhoea—Cisplatin—bone cancer	0.000383	0.00212	CcSEcCtD
Eprosartan—Bradycardia—Doxorubicin—bone cancer	0.000381	0.00211	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MMP2—bone cancer	0.00038	0.0187	CbGpPWpGaD
Eprosartan—Tinnitus—Epirubicin—bone cancer	0.000378	0.00209	CcSEcCtD
Eprosartan—Rhinitis—Doxorubicin—bone cancer	0.000376	0.00207	CcSEcCtD
Eprosartan—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000374	0.0184	CbGpPWpGaD
Eprosartan—Pharyngitis—Doxorubicin—bone cancer	0.000372	0.00205	CcSEcCtD
Eprosartan—Oedema peripheral—Doxorubicin—bone cancer	0.000369	0.00204	CcSEcCtD
Eprosartan—Back pain—Methotrexate—bone cancer	0.000364	0.00201	CcSEcCtD
Eprosartan—Chills—Epirubicin—bone cancer	0.000363	0.00201	CcSEcCtD
Eprosartan—Visual impairment—Doxorubicin—bone cancer	0.000361	0.00199	CcSEcCtD
Eprosartan—Vomiting—Cisplatin—bone cancer	0.000356	0.00197	CcSEcCtD
Eprosartan—Rash—Cisplatin—bone cancer	0.000353	0.00195	CcSEcCtD
Eprosartan—Dermatitis—Cisplatin—bone cancer	0.000353	0.00195	CcSEcCtD
Eprosartan—Ill-defined disorder—Methotrexate—bone cancer	0.000349	0.00193	CcSEcCtD
Eprosartan—Tinnitus—Doxorubicin—bone cancer	0.000349	0.00193	CcSEcCtD
Eprosartan—Flatulence—Epirubicin—bone cancer	0.000347	0.00192	CcSEcCtD
Eprosartan—Tension—Epirubicin—bone cancer	0.000346	0.00191	CcSEcCtD
Eprosartan—Nervousness—Epirubicin—bone cancer	0.000342	0.00189	CcSEcCtD
Eprosartan—Back pain—Epirubicin—bone cancer	0.000341	0.00188	CcSEcCtD
Eprosartan—Malaise—Methotrexate—bone cancer	0.00034	0.00188	CcSEcCtD
Eprosartan—Muscle spasms—Epirubicin—bone cancer	0.000339	0.00187	CcSEcCtD
Eprosartan—Vertigo—Methotrexate—bone cancer	0.000338	0.00187	CcSEcCtD
Eprosartan—Chills—Doxorubicin—bone cancer	0.000336	0.00186	CcSEcCtD
Eprosartan—Nausea—Cisplatin—bone cancer	0.000333	0.00184	CcSEcCtD
Eprosartan—Cough—Methotrexate—bone cancer	0.000329	0.00182	CcSEcCtD
Eprosartan—Ill-defined disorder—Epirubicin—bone cancer	0.000327	0.00181	CcSEcCtD
Eprosartan—Flatulence—Doxorubicin—bone cancer	0.000321	0.00178	CcSEcCtD
Eprosartan—Chest pain—Methotrexate—bone cancer	0.000321	0.00177	CcSEcCtD
Eprosartan—Arthralgia—Methotrexate—bone cancer	0.000321	0.00177	CcSEcCtD
Eprosartan—Myalgia—Methotrexate—bone cancer	0.000321	0.00177	CcSEcCtD
Eprosartan—Tension—Doxorubicin—bone cancer	0.00032	0.00177	CcSEcCtD
Eprosartan—Malaise—Epirubicin—bone cancer	0.000318	0.00176	CcSEcCtD
Eprosartan—Discomfort—Methotrexate—bone cancer	0.000317	0.00175	CcSEcCtD
Eprosartan—Nervousness—Doxorubicin—bone cancer	0.000317	0.00175	CcSEcCtD
Eprosartan—Vertigo—Epirubicin—bone cancer	0.000317	0.00175	CcSEcCtD
Eprosartan—Syncope—Epirubicin—bone cancer	0.000316	0.00175	CcSEcCtD
Eprosartan—Back pain—Doxorubicin—bone cancer	0.000315	0.00174	CcSEcCtD
Eprosartan—Muscle spasms—Doxorubicin—bone cancer	0.000314	0.00173	CcSEcCtD
Eprosartan—Palpitations—Epirubicin—bone cancer	0.000311	0.00172	CcSEcCtD
Eprosartan—Loss of consciousness—Epirubicin—bone cancer	0.00031	0.00171	CcSEcCtD
Eprosartan—Cough—Epirubicin—bone cancer	0.000308	0.0017	CcSEcCtD
Eprosartan—AGTR1—Arf6 signaling events—EGFR—bone cancer	0.000307	0.0151	CbGpPWpGaD
Eprosartan—Ill-defined disorder—Doxorubicin—bone cancer	0.000303	0.00167	CcSEcCtD
Eprosartan—Thrombocytopenia—Methotrexate—bone cancer	0.000301	0.00166	CcSEcCtD
Eprosartan—Arthralgia—Epirubicin—bone cancer	0.0003	0.00166	CcSEcCtD
Eprosartan—Chest pain—Epirubicin—bone cancer	0.0003	0.00166	CcSEcCtD
Eprosartan—Myalgia—Epirubicin—bone cancer	0.0003	0.00166	CcSEcCtD
Eprosartan—Anxiety—Epirubicin—bone cancer	0.000299	0.00165	CcSEcCtD
Eprosartan—Hyperhidrosis—Methotrexate—bone cancer	0.000297	0.00164	CcSEcCtD
Eprosartan—Discomfort—Epirubicin—bone cancer	0.000296	0.00164	CcSEcCtD
Eprosartan—Malaise—Doxorubicin—bone cancer	0.000294	0.00162	CcSEcCtD
Eprosartan—Dry mouth—Epirubicin—bone cancer	0.000293	0.00162	CcSEcCtD
Eprosartan—Vertigo—Doxorubicin—bone cancer	0.000293	0.00162	CcSEcCtD
Eprosartan—Anorexia—Methotrexate—bone cancer	0.000293	0.00162	CcSEcCtD
Eprosartan—Syncope—Doxorubicin—bone cancer	0.000292	0.00162	CcSEcCtD
Eprosartan—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000288	0.0142	CbGpPWpGaD
Eprosartan—Palpitations—Doxorubicin—bone cancer	0.000288	0.00159	CcSEcCtD
Eprosartan—Hypotension—Methotrexate—bone cancer	0.000287	0.00159	CcSEcCtD
Eprosartan—Loss of consciousness—Doxorubicin—bone cancer	0.000287	0.00158	CcSEcCtD
Eprosartan—Cough—Doxorubicin—bone cancer	0.000285	0.00157	CcSEcCtD
Eprosartan—Shock—Epirubicin—bone cancer	0.000283	0.00156	CcSEcCtD
Eprosartan—AGTR1—G alpha (q) signalling events—GNA11—bone cancer	0.000283	0.0139	CbGpPWpGaD
Eprosartan—Thrombocytopenia—Epirubicin—bone cancer	0.000282	0.00156	CcSEcCtD
Eprosartan—Tachycardia—Epirubicin—bone cancer	0.000281	0.00155	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00028	0.00155	CcSEcCtD
Eprosartan—Hyperhidrosis—Epirubicin—bone cancer	0.000278	0.00154	CcSEcCtD
Eprosartan—Insomnia—Methotrexate—bone cancer	0.000278	0.00154	CcSEcCtD
Eprosartan—Arthralgia—Doxorubicin—bone cancer	0.000278	0.00153	CcSEcCtD
Eprosartan—Chest pain—Doxorubicin—bone cancer	0.000278	0.00153	CcSEcCtD
Eprosartan—Myalgia—Doxorubicin—bone cancer	0.000278	0.00153	CcSEcCtD
Eprosartan—Anxiety—Doxorubicin—bone cancer	0.000277	0.00153	CcSEcCtD
Eprosartan—Paraesthesia—Methotrexate—bone cancer	0.000276	0.00152	CcSEcCtD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000275	0.0135	CbGpPWpGaD
Eprosartan—Discomfort—Doxorubicin—bone cancer	0.000274	0.00152	CcSEcCtD
Eprosartan—Anorexia—Epirubicin—bone cancer	0.000274	0.00151	CcSEcCtD
Eprosartan—Dyspnoea—Methotrexate—bone cancer	0.000274	0.00151	CcSEcCtD
Eprosartan—Somnolence—Methotrexate—bone cancer	0.000273	0.00151	CcSEcCtD
Eprosartan—Dry mouth—Doxorubicin—bone cancer	0.000272	0.0015	CcSEcCtD
Eprosartan—Dyspepsia—Methotrexate—bone cancer	0.000271	0.00149	CcSEcCtD
Eprosartan—Hypotension—Epirubicin—bone cancer	0.000269	0.00148	CcSEcCtD
Eprosartan—Decreased appetite—Methotrexate—bone cancer	0.000267	0.00148	CcSEcCtD
Eprosartan—Fatigue—Methotrexate—bone cancer	0.000265	0.00146	CcSEcCtD
Eprosartan—Pain—Methotrexate—bone cancer	0.000263	0.00145	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000262	0.00145	CcSEcCtD
Eprosartan—Shock—Doxorubicin—bone cancer	0.000262	0.00145	CcSEcCtD
Eprosartan—Thrombocytopenia—Doxorubicin—bone cancer	0.000261	0.00144	CcSEcCtD
Eprosartan—Insomnia—Epirubicin—bone cancer	0.00026	0.00144	CcSEcCtD
Eprosartan—Tachycardia—Doxorubicin—bone cancer	0.00026	0.00144	CcSEcCtD
Eprosartan—Paraesthesia—Epirubicin—bone cancer	0.000258	0.00143	CcSEcCtD
Eprosartan—Hyperhidrosis—Doxorubicin—bone cancer	0.000257	0.00142	CcSEcCtD
Eprosartan—Dyspnoea—Epirubicin—bone cancer	0.000256	0.00142	CcSEcCtD
Eprosartan—Somnolence—Epirubicin—bone cancer	0.000256	0.00141	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—GRM4—bone cancer	0.000255	0.0126	CbGpPWpGaD
Eprosartan—Anorexia—Doxorubicin—bone cancer	0.000254	0.0014	CcSEcCtD
Eprosartan—Feeling abnormal—Methotrexate—bone cancer	0.000253	0.0014	CcSEcCtD
Eprosartan—Dyspepsia—Epirubicin—bone cancer	0.000253	0.0014	CcSEcCtD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000253	0.0124	CbGpPWpGaD
Eprosartan—Gastrointestinal pain—Methotrexate—bone cancer	0.000251	0.00139	CcSEcCtD
Eprosartan—Decreased appetite—Epirubicin—bone cancer	0.00025	0.00138	CcSEcCtD
Eprosartan—Hypotension—Doxorubicin—bone cancer	0.000249	0.00137	CcSEcCtD
Eprosartan—Fatigue—Epirubicin—bone cancer	0.000248	0.00137	CcSEcCtD
Eprosartan—Constipation—Epirubicin—bone cancer	0.000246	0.00136	CcSEcCtD
Eprosartan—Pain—Epirubicin—bone cancer	0.000246	0.00136	CcSEcCtD
Eprosartan—Urticaria—Methotrexate—bone cancer	0.000244	0.00135	CcSEcCtD
Eprosartan—Abdominal pain—Methotrexate—bone cancer	0.000243	0.00134	CcSEcCtD
Eprosartan—Body temperature increased—Methotrexate—bone cancer	0.000243	0.00134	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000242	0.00134	CcSEcCtD
Eprosartan—Insomnia—Doxorubicin—bone cancer	0.000241	0.00133	CcSEcCtD
Eprosartan—Paraesthesia—Doxorubicin—bone cancer	0.000239	0.00132	CcSEcCtD
Eprosartan—Dyspnoea—Doxorubicin—bone cancer	0.000237	0.00131	CcSEcCtD
Eprosartan—Feeling abnormal—Epirubicin—bone cancer	0.000237	0.00131	CcSEcCtD
Eprosartan—Somnolence—Doxorubicin—bone cancer	0.000237	0.00131	CcSEcCtD
Eprosartan—Gastrointestinal pain—Epirubicin—bone cancer	0.000235	0.0013	CcSEcCtD
Eprosartan—Dyspepsia—Doxorubicin—bone cancer	0.000234	0.00129	CcSEcCtD
Eprosartan—Decreased appetite—Doxorubicin—bone cancer	0.000231	0.00128	CcSEcCtD
Eprosartan—Fatigue—Doxorubicin—bone cancer	0.000229	0.00127	CcSEcCtD
Eprosartan—Urticaria—Epirubicin—bone cancer	0.000229	0.00126	CcSEcCtD
Eprosartan—Pain—Doxorubicin—bone cancer	0.000228	0.00126	CcSEcCtD
Eprosartan—Constipation—Doxorubicin—bone cancer	0.000228	0.00126	CcSEcCtD
Eprosartan—Abdominal pain—Epirubicin—bone cancer	0.000227	0.00126	CcSEcCtD
Eprosartan—Body temperature increased—Epirubicin—bone cancer	0.000227	0.00126	CcSEcCtD
Eprosartan—Hypersensitivity—Methotrexate—bone cancer	0.000226	0.00125	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—GRM1—bone cancer	0.000221	0.0109	CbGpPWpGaD
Eprosartan—Asthenia—Methotrexate—bone cancer	0.000221	0.00122	CcSEcCtD
Eprosartan—Feeling abnormal—Doxorubicin—bone cancer	0.000219	0.00121	CcSEcCtD
Eprosartan—Gastrointestinal pain—Doxorubicin—bone cancer	0.000218	0.0012	CcSEcCtD
Eprosartan—Pruritus—Methotrexate—bone cancer	0.000217	0.0012	CcSEcCtD
Eprosartan—Hypersensitivity—Epirubicin—bone cancer	0.000212	0.00117	CcSEcCtD
Eprosartan—Urticaria—Doxorubicin—bone cancer	0.000211	0.00117	CcSEcCtD
Eprosartan—Body temperature increased—Doxorubicin—bone cancer	0.00021	0.00116	CcSEcCtD
Eprosartan—Abdominal pain—Doxorubicin—bone cancer	0.00021	0.00116	CcSEcCtD
Eprosartan—Diarrhoea—Methotrexate—bone cancer	0.00021	0.00116	CcSEcCtD
Eprosartan—Asthenia—Epirubicin—bone cancer	0.000206	0.00114	CcSEcCtD
Eprosartan—Pruritus—Epirubicin—bone cancer	0.000204	0.00112	CcSEcCtD
Eprosartan—Dizziness—Methotrexate—bone cancer	0.000203	0.00112	CcSEcCtD
Eprosartan—Diarrhoea—Epirubicin—bone cancer	0.000197	0.00109	CcSEcCtD
Eprosartan—Hypersensitivity—Doxorubicin—bone cancer	0.000196	0.00108	CcSEcCtD
Eprosartan—Vomiting—Methotrexate—bone cancer	0.000195	0.00108	CcSEcCtD
Eprosartan—Rash—Methotrexate—bone cancer	0.000194	0.00107	CcSEcCtD
Eprosartan—Dermatitis—Methotrexate—bone cancer	0.000194	0.00107	CcSEcCtD
Eprosartan—Headache—Methotrexate—bone cancer	0.000193	0.00106	CcSEcCtD
Eprosartan—Asthenia—Doxorubicin—bone cancer	0.000191	0.00105	CcSEcCtD
Eprosartan—Dizziness—Epirubicin—bone cancer	0.00019	0.00105	CcSEcCtD
Eprosartan—Pruritus—Doxorubicin—bone cancer	0.000188	0.00104	CcSEcCtD
Eprosartan—Vomiting—Epirubicin—bone cancer	0.000183	0.00101	CcSEcCtD
Eprosartan—Nausea—Methotrexate—bone cancer	0.000183	0.00101	CcSEcCtD
Eprosartan—Diarrhoea—Doxorubicin—bone cancer	0.000182	0.00101	CcSEcCtD
Eprosartan—Rash—Epirubicin—bone cancer	0.000181	0.001	CcSEcCtD
Eprosartan—Dermatitis—Epirubicin—bone cancer	0.000181	0.001	CcSEcCtD
Eprosartan—Headache—Epirubicin—bone cancer	0.00018	0.000996	CcSEcCtD
Eprosartan—Dizziness—Doxorubicin—bone cancer	0.000176	0.000972	CcSEcCtD
Eprosartan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000174	0.00859	CbGpPWpGaD
Eprosartan—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000172	0.00848	CbGpPWpGaD
Eprosartan—Nausea—Epirubicin—bone cancer	0.000171	0.000944	CcSEcCtD
Eprosartan—Vomiting—Doxorubicin—bone cancer	0.000169	0.000935	CcSEcCtD
Eprosartan—Rash—Doxorubicin—bone cancer	0.000168	0.000927	CcSEcCtD
Eprosartan—Dermatitis—Doxorubicin—bone cancer	0.000168	0.000926	CcSEcCtD
Eprosartan—Headache—Doxorubicin—bone cancer	0.000167	0.000921	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—TGFBR2—bone cancer	0.000167	0.00821	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—GSTP1—bone cancer	0.000167	0.00821	CbGpPWpGaD
Eprosartan—Nausea—Doxorubicin—bone cancer	0.000158	0.000873	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—SMO—bone cancer	0.000156	0.00768	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—RGS1—bone cancer	0.000144	0.0071	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—GRM4—bone cancer	0.000144	0.0071	CbGpPWpGaD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000141	0.00696	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000131	0.00646	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—RGS1—bone cancer	0.000131	0.00645	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—GRM4—bone cancer	0.000131	0.00645	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—GRM1—bone cancer	0.000125	0.00616	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—GRM1—bone cancer	0.000113	0.00559	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000113	0.00557	CbGpPWpGaD
Eprosartan—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	8.94e-05	0.0044	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—GNA11—bone cancer	8.05e-05	0.00397	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—SMO—bone cancer	7.99e-05	0.00394	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—GRM4—bone cancer	7.73e-05	0.00381	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—RGS1—bone cancer	7.73e-05	0.00381	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—CYP3A4—bone cancer	7.51e-05	0.0037	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	7.4e-05	0.00365	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—GNA11—bone cancer	7.31e-05	0.0036	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—IL3—bone cancer	7.3e-05	0.0036	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	7.19e-05	0.00354	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—GRM1—bone cancer	6.7e-05	0.0033	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—IL3—bone cancer	6.63e-05	0.00327	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—GSTP1—bone cancer	6.42e-05	0.00316	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	6.33e-05	0.00312	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SMO—bone cancer	4.72e-05	0.00233	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NDUFA12—bone cancer	4.5e-05	0.00222	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—GNA11—bone cancer	4.32e-05	0.00213	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ATF1—bone cancer	4.02e-05	0.00198	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IL3—bone cancer	3.92e-05	0.00193	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NT5C3A—bone cancer	3.73e-05	0.00184	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TGFBR2—bone cancer	3.35e-05	0.00165	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IGF1R—bone cancer	3.15e-05	0.00155	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KIT—bone cancer	2.29e-05	0.00113	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—BRAF—bone cancer	2.15e-05	0.00106	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—EGFR—bone cancer	2.08e-05	0.00103	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MDM2—bone cancer	1.8e-05	0.000887	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ENO2—bone cancer	1.63e-05	0.000805	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—JUN—bone cancer	1.56e-05	0.000771	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MMP9—bone cancer	1.52e-05	0.00075	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—DHFR—bone cancer	1.52e-05	0.000747	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GNA11—bone cancer	1.42e-05	0.000698	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP3A4—bone cancer	1.28e-05	0.000633	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.28e-05	0.000629	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—EGFR—bone cancer	1.23e-05	0.000606	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTP1—bone cancer	1.1e-05	0.000541	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TP53—bone cancer	1.03e-05	0.000509	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PTGS2—bone cancer	5.69e-06	0.00028	CbGpPWpGaD
